StockData
FibroBiologics, Inc. logo

FibroBiologics, Inc. (FBLG) stock

FBLGNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 2/30
$0.83−0.01 (-1.19%)

Close on Nov 19, 2026Market cap $5.53MP/E –Yield –

FibroBiologics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

FibroBiologics's free cash flow for the twelve months ending Jun 30, 2026 was -$14.80M. For fiscal 2025 it was -$16.66M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$16.66M–
FY2024Dec 31, 2024-$12.09M–
FY2023Dec 31, 2023-$6.90M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.29M–
Q1 FY2026Mar 31, 2026-$4.36M–
Q4 FY2025Dec 31, 2025-$3.16M–
Q3 FY2025Sep 30, 2025-$3.98M–
Q2 FY2025Jun 30, 2025-$4.20M–
Q1 FY2025Mar 31, 2025-$5.32M–
Q4 FY2024Dec 31, 2024-$3.17M–
Q3 FY2024Sep 30, 2024-$2.62M–
Q2 FY2024Jun 30, 2024-$2.01M–
Q1 FY2024Mar 31, 2024-$4.28M–
Q4 FY2023Dec 31, 2023-$1.60M–
Q3 FY2023Sep 30, 2023-$1.55M–
Q2 FY2023Jun 30, 2023-$1.65M–
Q1 FY2023Mar 31, 2023-$2.09M–

More FibroBiologics figures

See a number that looks wrong?